View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2014	Nov. 24, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	PROTEON THERAPEUTICS INC
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		16,449,164
Amendment Flag	false
Entity Central Index Key	0001359931
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Series A-1 Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock,	$ 18,003	$ 17,374
Series B Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock,	29,083	27,401
Series C Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock,	18,265	17,400
Series D Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock,	25,402
Cash and cash equivalents	3,239	2,793
Available-for-sale investments	18,447	2,359
Prepaid expenses	168	61
Other current assets	27	78
Short-term deposits	39	39
Total current assets	21,920	5,330
Property and equipment, net	86	62
Deferred tax asset		267
Other non-current assets	2,173
Total assets	24,179	5,659
Convertible notes, including accrued interest of $0 and $112 as of September 30, 2014 and December 31, 2013, respectively		3,727
Derivative liability		1,443
Accounts payable	1,048	399
Accrued expenses	1,610	984
Deferred tax liability		267
Current portion of deferred revenue from sale of option to acquire company		2,948
Total current liabilities	2,658	9,768
Investors' rights/obligations	11,903
Total liabilities	14,561	9,768
Commitments and contingencies
Redeemable convertible preferred stock,	35,416	34,230
Stockholders’ equity (deficit):
Accumulated deficit	(116,540)	(100,514)
Accumulated other comprehensive loss	(11)
Total stockholders’ deficit	(116,551)	(100,514)
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit	$ 24,179	$ 5,659

Consolidated Balance Sheets (unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Series A Preferred Stock [Member]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	22,638,465	22,638,465
Redeemable convertible preferred stock, shares issued	22,638,465	22,638,465
Redeemable convertible preferred stock shares outstanding	22,638,465	22,638,465
Redeemable convertible preferred stock, aggregate liquidation preference (in Dollars)	$ 12,288	$ 22,638
Series A-1 Preferred Stock [Member]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	10,909,091	10,909,091
Redeemable convertible preferred stock, shares issued	10,909,091	10,909,091
Redeemable convertible preferred stock shares outstanding	10,909,091	10,909,091
Redeemable convertible preferred stock, aggregate liquidation preference (in Dollars)	$ 6,514	$ 12,000
Series B Preferred Stock [Member]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	20,754,461	20,754,461
Redeemable convertible preferred stock, shares issued	20,754,461	20,754,461
Redeemable convertible preferred stock shares outstanding	20,754,461	20,754,461
Redeemable convertible preferred stock, aggregate liquidation preference (in Dollars)	$ 12,955	$ 23,867
Series C Preferred Stock [Member]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	17,550,758	17,550,758
Redeemable convertible preferred stock, shares issued	13,202,932	13,202,932
Redeemable convertible preferred stock shares outstanding	13,202,932	13,202,932
Redeemable convertible preferred stock, aggregate liquidation preference (in Dollars)	$ 8,241	$ 15,183
Series D Preferred Stock [Member]
Redeemable convertible preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	86,789,527	0
Redeemable convertible preferred stock, shares issued	52,813,827	0
Redeemable convertible preferred stock shares outstanding	52,813,827	0
Redeemable convertible preferred stock, aggregate liquidation preference (in Dollars)	$ 31,089	$ 0
Convertible notes, accrued interest payable (in Dollars)	$ 0	$ 112
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	205,926,290	100,370,203
Common stock, shares issued	240,614	239,905
Common stock, shares outstanding	240,614	239,905

Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	$ 2,948		$ 2,948
Operating expenses:
Research and development	1,773	$ 971	4,558	$ 2,974
General and administrative	1,041	943	2,697	2,360
Total operating expenses	2,814	1,914	7,255	5,334
Income (loss) from operations	134	(1,914)	(4,307)	(5,334)
Other income (expense):
Interest income (expense), net	10	(171)	(844)	(168)
Other expense	(5,325)	(18)	(5,424)	(13)
Other expense, net	(5,315)	(189)	(6,268)	(181)
Net loss	(5,181)	(2,103)	(10,575)	(5,515)
Unrealized gain (loss) on available-for-sale investments	12	(1)	(11)	(1)
Comprehensive loss	(5,169)	(2,104)	(10,586)	(5,516)
Reconciliation of net loss to net loss attributable to common stockholders
Net loss	(5,181)	(2,103)	(10,575)	(5,515)
Accretion of redeemable convertible preferred stock to redemption value	(2,277)	(1,540)	(5,686)	(4,579)
Net loss attributable to common stockholders	$ (7,458)	$ (3,643)	$ (16,261)	$ (10,094)
Net loss per share attributable to common stockholders - basic and diluted (in Dollars per share)	$ (31.03)	$ (15.60)	$ (67.65)	$ (43.21)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted (in Shares)	240,375	233,586	240,375	233,586

Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Early Exercise of Stock Options [Member]
Financing activities
Exercise of stock options		$ 2,000
Net loss	$ (10,575,000)	(5,515,000)
Depreciation	21,000	21,000
Amortization of premium/discount on available-for-sale securities	18,000	21,000
Gain on sale of fixed assets		(7,000)
Accretion of discount & debt issuance cost of convertible notes payable	742,000	146,000
Stock-based compensation	234,000	126,000
Change in fair value of investor rights/obligation	5,344,000
Change in fair value of derivative liability	81,000	20,000
Prepaid expenses and other current assets	(2,234,000)	128,000
Interest receivable	(13,000)	15,000
Accounts payable and accrued expenses	1,275,000	111,000
Accrued interest payable	115,000	25,000
Deferred revenue from sale of acquisition option to acquire company	(2,948,000)
Net cash used in operating activities	(7,940,000)	(4,909,000)
Purchases of available-for-sale investments	(19,697,000)	(1,510,000)
Proceeds from maturities of available for sale investments	3,580,000	6,550,000
Purchase of property and equipment	(45,000)	(1,000)
Sale of property and equipment		7,000
Net cash (used in) provided by investing activities	(16,162,000)	5,046,000
Proceeds from issuance of Series D preferred stock	25,000,000
Issuance costs for preferred stock	(452,000)
Proceeds from issuance of convertible notes payable		4,339,000
Payments for debt issuance costs		(46,000)
Exercise of stock options		19,000
Net cash provided by financing activities	24,548,000	4,314,000
Increase in cash and cash equivalents	446,000	4,451,000
Cash and cash equivalents, beginning of period	2,793,000	2,409,000
Cash and cash equivalents, end of period	3,239,000	6,860,000
Supplemental disclosure of non-cash investing and financing activities
Accretion of redeemable convertible preferred stock to redemption value	5,686,000	4,579,000
Fair value of embedded derivative contained within convertible notes payable		$ 1,443,000
Conversion of convertible notes, including accrued interest, into Series D Redeemable Convertible Preferred Stock	$ 4,565,000

Note 1 - Organization and Operations

9 Months Ended

Sep. 30, 2014

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

1.	Organization and operations

The Company

Proteon Therapeutics, Inc. (the “Company”) is an early-stage biopharmaceutical company engaged in the development of elastases to treat the growing medical needs of renal and vascular disease patients. The Company was formed in June 2001 and later was incorporated on March 24, 2006. During 2013, the Company formed a wholly-owned subsidiary, organized in the United Kingdom. As of September 30, 2014, there has been no activity in this subsidiary other than its formation. The Company completed its initial public offering of its common stock, $0.001 par value per share (“Common Stock”) on October 27, 2014 (the “IPO”). Since inception, the Company has been primarily involved in research and development activities.

The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has not generated any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the life sciences industry, including regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key individuals.

The Company had an accumulated deficit of $116.5 million as of September 30, 2014. The Company had cash, cash equivalents and investments of $21.7 million as of September 30, 2014. Including the proceeds from its IPO , which closed on October 27, 2014 (see Note 11), the Company believes that its existing cash and cash equivalents and available-for-sale investments will be sufficient to fund operations and capital expenditures into 2018.

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.	Summary of Significant accounting policies

Basis of presentation and use of estimates

The unaudited interim consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these consolidated financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, 2013 and the six months ended June 30, 2014 and notes thereto, included in the Company’s final prospectus dated October 21, 2104 filed with the SEC pursuant to Rule 424(b)(4) on October 22, 2014 (the “Prospectus”).

The unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim consolidated financial statements contain all adjustments which are necessary to fairly present the Company’s financial position as of September 30, 2014, the results of its operations for the three and nine months ended September 30, 2014 and 2013 and its cash flows for the nine months ended September 30, 2014 and 2013. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results for the year ending December 31, 2014, or for any future period.

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to clinical trial accruals, stock-based compensation expense, warrants to purchase redeemable securities, the investors rights obligation and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The Company utilized various valuation methodologies in accordance with the framework of the 2004 and 2013 American Institute of Certified Public Accountants Technical Practice Aids, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its Common Stock. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date and materially affect the financial statements.

Deferred initial public offering costs

Deferred public offering costs, which primarily consist of direct, incremental legal and accounting fees related to the IPO, were capitalized within other assets as of September 30, 2014. The Company incurred $2.8 million in IPO-related costs and in October 2014, these public offering costs were offset against the proceeds upon completion of the IPO.

Fair value of financial instruments

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures, established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available under the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. Fair value measurements are classified and disclosed in one of the following three categories:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.

Financial instruments measured at fair value on a recurring basis include cash equivalents and government securities. There have been no changes to the valuation methods utilized by the Company during the three and nine months ended September 30, 2014 and 2013. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the three and nine months ended September 30, 2014 and 2013.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition providing a single, comprehensive revenue recognition model for all contracts with customers. The new revenue standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard is effective beginning January 1, 2017, with no early adoption permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. We are currently evaluating the impact of the new guidance on our consolidated financial statements, if any.

In June 2014, the FASB issued authoritative guidance regarding disclosure requirements of development stage companies in GAAP and International Financial Reporting Standards. This newly issued accounting standard removes all incremental financial reporting requirements, including inception-to-date information, for development stage entities. This guidance is effective for annual periods beginning after December 15, 2014. However, the Company adopted this guidance early effective with the publication of its 2013 financial statements.

In August 2014, the FASB issued authoritative guidance regarding on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements, including requiring management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements and providing certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. This guidance will be effective for the Company’s fiscal year 2016 and for interim periods beginning in the first quarter of fiscal 2017. The Company is still evaluating the impact of this guidance on its financial statement disclosures.

There have been no other material changes to the significant accounting policies previously disclosed in the Company’s Prospectus.

Note 3 - Financial Instruments

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3.	Financial Instruments

Below is a summary of assets and liabilities measured at fair value as of September 30, 2014 and December 31, 2013:

	As of September 30, 2014
	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Financial assets
Cash equivalents	$	3,233	$	-	$	-	$	3,233
Government securities		18,447		-		-		18,447
Total	$	21,680	$	-	$	-	$	21,680

Financial liabilities
Derivative liability	$	-	$	-	$	11,903	$	11,903
Total	$	-	$	-	$	11,903	$	11,903

	As of December 31, 2013
	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Financial assets
Cash equivalents	$	2,781	$	-	$	-	$	2,781
Government securities		2,359		-		-		2,359
Total	$	5,140	$	-	$	-	$	5,140

Financial liabilities
Derivative liability		-		-		1,443		1,443
Total	$	-	$	-	$	1,443	$	1,443

The Company's cash equivalents consist principally of money market funds. Government securities consist principally of government debt securities and money market funds which are classified as available-for-sale. Cash equivalents and government securities are stated at fair value and consist of Level 1 financial instruments in the fair value hierarchy. The Company determines the fair value of its debt security holdings based on pricing from a service provider. The service provider values the securities based on market prices from a variety of industry-standard independent data providers. Such market prices are quoted prices in active markets for identical assets (Level 1 inputs).

The derivative liability and investors rights and obligations are considered Level 3 inputs because their fair value measurement is based, in part, on significant inputs not observed in the market. Any reasonable changes in the assumptions used in the valuation could materially affect the financial results of the Company. The derivative liability was extinguished upon the conversion of the convertible promissory notes (the “Convertible Notes”) into Series D Preferred Stock in May 2014. The Series D investors’ rights and obligations were either exercised or extinguished upon the completion of the Company’s IPO.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Convertible Notes

9 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

4.	Convertible Notes

On September 4, 2013, the Company issued Convertible Notes for total aggregate proceeds of $4.3 million. All of the Convertible Notes were purchased by existing preferred stockholders. The Convertible Notes accrued interest at 8% per annum and matured on or after March 31, 2014 upon written notice from a majority of the outstanding Convertible Note holders.

In connection with the issuance of the Convertible Notes, the Company incurred $36,000 of financing costs which were recorded in other current assets. The Company also reimbursed the lenders $10,000 for financing costs which were recorded as a discount on the Convertible Notes. The Convertible Notes included various embedded conversion and redemption features. The Company recorded approximately $1.4 million as the fair value of the combined embedded derivative liability on September 4, 2013, with a corresponding amount recorded as debt discount. The debt discount has been amortized to interest expense over the life of the Convertible Notes. Amounts recorded for issuance costs and embedded features were amortized to interest expense over the life of the Convertible Notes, approximately seven months. Changes in the estimated fair value of the embedded features were recorded in earnings in the period in which they occurred. As of December 31, 2013, the fair value of the combined embedded derivative liability was $1.4 million.

On May 13, 2014, the Convertible Notes, including accrued interest, were converted into 10,344,201 shares of Series D Preferred Stock at a conversion price of $0.4414 per share. In connection with the conversion, the compound embedded derivative liability, which had a fair value of $1.5 million upon conversion, was written-off. There was no gain or loss recognized upon conversion of the Convertible Notes.

Note 5 - Option to Acquire the Company

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

5.	Option to acquire the Company

In March 2009, the Company entered into an option agreement with a major pharmaceutical entity that provided an exclusive option to acquire the Company under a pre-negotiated merger agreement. The Company received a $10.0 million non-refundable payment as consideration for the agreement. The fair value of the option to acquire the Company was estimated at $7.1 million using the Black-Scholes option-pricing model, which was recorded as additional paid-in capital during 2009. The $2.9 million difference between the $10.0 million non-refundable payment and the fair value of the option was recorded as deferred revenue during 2009, representing the value of certain residual rights in the event the acquisition option is not exercised (e.g., a right, under certain circumstances, to license the Company's underlying technology). The acquisition option expired unexercised in 2013. On August 3, 2014, the residual rights under this option agreement lapsed and the $2.9 million in deferred revenue was recognized as revenue on that date.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Note 6 - Redeemable Convertible Preferred Stock

9 Months Ended

Sep. 30, 2014

Redeemable Convertible Preferred Stock [Abstract]

Redeemable Convertible Preferred Stock [Text Block]

6.	Redeemable Convertible Preferred Stock

As of September 30, 2014, the total authorized capital stock of the Company was 364,568,592 shares, which included 22,638,465 shares of Series A Preferred Stock, $0.001 par value per share; 10,909,091 shares of Series A-1 Preferred Stock, $0.001 par value per share; 20,754,461 shares of Series B Preferred Stock, $0.001 par value per share; 17,550,758 shares of Series C Preferred Stock, $0.001 par value per share; and 86,789,527 shares of Series D Preferred Stock, $0.001 par value per share.

On May 13, 2014, the Company issued 42,469,626 shares of Series D Preferred Stock to new and existing investors at a price of $0.588656 per share for gross proceeds of $25.0 million. Immediately upon closing this round of financing, $4.6 million of Convertible Notes, including $0.2 million of accrued and unpaid interest, automatically converted into 10,344,201 shares of Series D Preferred Stock at a conversion price of $0.4414 per share.

The Series D Purchase agreement contemplates the sale in two additional subsequent closings (the “second and third tranches”) of up to 33,975,700 additional shares of the Company’s Series D Preferred Stock for aggregate gross proceeds of $20.0 million. Both the Company and the tranche right holders have the right to exercise these tranche features. However, the Company’s right is contingent upon the achievement of certain pre-defined milestones and terminates at the closing of an IPO. The holders of the tranche rights have the ability to exercise the second and third tranche rights to purchase additional shares of the Company’s Series D Preferred Stock at any time prior to an IPO and excluding certain black-out dates. The Series D Purchase Agreement also provides to the Series D investors party to the agreement certain individual purchase rights, as outlined in the Company’s Prospectus.

As described above, in connection with the issuance of the Series D Preferred Stock, the holders received rights to purchase additional shares of Series D Preferred Stock at $0.588656 per share. These investor rights represent freestanding financial instruments, and are accounted for as liabilities. The Company adjusts the carrying value of these investor rights to fair value at each reporting date up to the closing of the tranche financing. Increases or decreases in the fair value of such investor rights are recorded as other income (expense) in the Consolidated Statements of Operations and Comprehensive Loss.

The estimated fair value of the tranche rights was determined upon issuance using a Black-Scholes option pricing model with the following inputs:

Expected term (in years)	1.84	-	3.50
Expected volatility	63.0%	-	86.0%
Risk-free interest rate	0.44%	-	1.12%
Expected dividend yield		0%

At the date of issuance, the investor rights and obligation was recorded at its fair value of $6.6 million as a liability on the balance sheet. The estimated fair value of the tranche rights was determined as of September 30, 2014 using a Black-Scholes option pricing model with the following inputs:

Expected term (in years)	1.34	-	3.00
Expected volatility	63.0%	-	71.0%
Risk-free interest rate	0.34%	-	1.05%
Expected dividend yield		0%

During the three and nine months ended September 30, 2014, the change in fair value of the investor rights was $5.3 million and $5.3 million, respectively, and was recorded as other expense in the Consolidated Statements of Operations and Comprehensive Loss.

The Company incurred approximately $0.5 million in costs related to the issuance of the Series D Preferred Stock which have been allocated to the shares issued to date and the tranche right liability. The $0.4 million of issuance costs allocated to the shares issued in May 2014 have been recorded as a discount on the Series D Preferred Stock and will be accreted over five years to the earliest redemption date of the Series D Preferred Stock. The remaining $0.1 million of issuance costs have been allocated to the tranche right liability.

Upon the closing of the Company’s IPO (see Note 11), all outstanding shares of the Company’s preferred stock were automatically converted into an aggregate of 8,651,805 shares of its Common Stock and the Series D preferred stock investors’ rights and obligations were either exercised or extinguished.

Note 7 - Common Stock

9 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

7.	Common Stock

At September 30, 2014, the Company had authorized 205,926,290 shares of Common Stock, $0.001 par value per share, of which 240,614 shares were issued and outstanding. The Company has reserved for future issuances the following number of shares of Common Stock:

	September 30, 2014		December 31, 2013
Conversion of Series A Preferred Stock		1,700,622		1,426,482
Conversion of Series A-1 Preferred Stock		838,101		687,395
Conversion of Series B Preferred Stock		1,610,383		1,307,771
Conversion of Series C Preferred Stock		1,361,809		1,105,907
Conversion of Series D Preferred Stock		3,327,894		-
Stock-based compensation awards		1,135,415		623,111
Warrants to purchase Common Stock		659,806		659,806
Total		10,634,030		5,810,472

Immediately prior to the closing of the Company’s IPO (see Note 11), 498,889 shares of Common Stock were issued upon the exercise of warrants with a weighted-average exercise price of $4.60 per share.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 8 - Stock-Based Compensation

9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

8.	Stock-based compensation

Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company’s statements of operations as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013

Research and development	$	47	$	14	$	68	$	98
General and administrative		138		7		166		28
Total	$	185	$	21	$	234	$	126

The following table summarizes stock option activity for employees and nonemployees:

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2013		607,017		$	2.22		5.2	$	1,627
Granted		527,718		$	4.92
Exercised		(709	)	$	1.27
Cancelled or forfeited		-		$	-
Outstanding at September 30, 2014		1,134,026		$	3.49		6.9	$	8,716
Exercisable at September 30, 2014		581,438		$	2.38		4.5	$	5,123
Vested or expected to vest at September 30, 2014		1,067,423		$	3.33		6.8	$	8,264

Note 9 - Income Taxes

9 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

9.	Income Taxes

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has provided a full valuation allowance against its deferred tax assets. There were no significant income tax provisions or benefits for the three or nine months ended September 30, 2014 and 2013.

Note 10 - Net Loss Per Share Attributable to Common Stockholders

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

10.	Net loss per share attributable to common stockholders

The Company computes basic and diluted earnings (loss) per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). As the three and nine month periods ended September 30, 2014 and 2013 resulted in net losses, there is no income allocation required under the two-class method or dilution attributed to weighted average shares outstanding in the calculation of diluted loss per share.

The following common stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible Preferred stock		7,581		4,254		7,581		4,254
Common stock warrants		660		660		660		660
Outstanding stock options		1,134		607		1,134		607
Convertible notes		-		239		-		239
		9,375		5,760		9,375		5,760

Note 11 - Subsequent Events

9 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

11.	Subsequent Events

Reverse stock split

On October 1, 2014, the Board of Directors and, on October 3, 2014, the stockholders approved a 1-for-15.87 reverse stock split of the Company's Common Stock and a proportional adjustment to the existing conversion ratios for each series of preferred stock. The effective date of the reverse stock split was October 6, 2014. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares upon the closing of the IPO. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of preferred stock are convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split. Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the consolidated financial statements disclose the adjusted conversion ratios.

Initial Public Offering

On October 21, 2014, the Company’s registration statement on Form S-1 (File No 333-198777) was declared effective for its IPO, pursuant to which the Company registered the offering and sale of 7,026,500 shares of common stock (including 916,500 shares upon exercise of an option by the underwriters) at a public offering price of $10 per share for an aggregate offering of $70.3 million. On October 27, 2014, we completed the sale of 6,110,000 shares of Common Stock and on November 21, 2014, we completed the sale of 916,500 shares of our Common Stock upon the exercise of an option by the Company’s underwriters to purchase additional shares.

As a result of the IPO, including the exercise of the underwriter’s over-allotment, the Company received net proceeds of approximately $62.5 million from the sale of 7,026,500 shares of common stock, after deducting approximately $7.7 million of underwriting discounts and commissions and estimated offering-related expenses payable by the Company.

Immediately prior to the closing of the Company’s IPO, 498,889 shares of Common Stock were issued upon the exercise of warrants with a weighted-average exercise price of $4.60 per share.

Upon the closing of the Company’s IPO, all outstanding shares of the Company’s preferred stock were automatically converted into an aggregate of 8,651,805 shares of its Common Stock and the Series D investors’ rights and obligations were either exercised or extinguished.

2014 Equity Incentive and Stock Purchase Plans

On August 21, 2014, the Board of Directors adopted the Proteon Therapeutics, Inc. 2014 Incentive Plan, the 2014 Employee Stock Purchase Plan and the 2006 Equity Incentive Plan, as amended and restated, and on October 3, 2014, the stockholders approved such plans.

The 2014 Equity Incentive Plan, which became effective immediately prior to effectiveness of the Company's IPO, provides for the grant of incentive stock option and nonstatutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The number of shares initially reserved for issuance under the 2014 Equity Incentive Plan is 704,000 shares of Common Stock and will be increased each January 1 starting in 2015 by an amount equal to the lesser of (i) four percent (4%) of our outstanding Common Stock on a fully diluted basis as of the end of our immediately preceding fiscal year, and (ii) any lower amount determined by our Board of Directors prior to each such January 1.

The 2014 Employee Stock Purchase Plan authorizes the issuance of up to 140,500 shares of Common Stock. The number of shares will be increased each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of (i) one percent (1%) of outstanding shares as of the end of the immediately preceding fiscal year, (ii) 281,000, and (iii) any lower amount determined by our Board of Directors prior to each such January 1.

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Basis of Presentation and Use of Estimates [Policy Text Block]

Basis of presentation and use of estimates

Deferred Charges, Policy [Policy Text Block]

Deferred initial public offering costs

Fair Value Measurement, Policy [Policy Text Block]

Fair value of financial instruments

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

Note 3 - Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	As of September 30, 2014
	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Financial assets
Cash equivalents	$	3,233	$	-	$	-	$	3,233
Government securities		18,447		-		-		18,447
Total	$	21,680	$	-	$	-	$	21,680

Financial liabilities
Derivative liability	$	-	$	-	$	11,903	$	11,903
Total	$	-	$	-	$	11,903	$	11,903

	As of December 31, 2013
	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Financial assets
Cash equivalents	$	2,781	$	-	$	-	$	2,781
Government securities		2,359		-		-		2,359
Total	$	5,140	$	-	$	-	$	5,140

Financial liabilities
Derivative liability		-		-		1,443		1,443
Total	$	-	$	-	$	1,443	$	1,443

Note 6 - Redeemable Convertible Preferred Stock (Tables)

9 Months Ended

Sep. 30, 2014

Redeemable Convertible Preferred Stock [Abstract]

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

Expected term (in years)	1.84	-	3.50
Expected volatility	63.0%	-	86.0%
Risk-free interest rate	0.44%	-	1.12%
Expected dividend yield		0%

Expected term (in years)	1.34	-	3.00
Expected volatility	63.0%	-	71.0%
Risk-free interest rate	0.34%	-	1.05%
Expected dividend yield		0%

Note 7 - Common Stock (Tables)

9 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Common Stock Reserve for Future Issuance [Table Text Block]

	September 30, 2014		December 31, 2013
Conversion of Series A Preferred Stock		1,700,622		1,426,482
Conversion of Series A-1 Preferred Stock		838,101		687,395
Conversion of Series B Preferred Stock		1,610,383		1,307,771
Conversion of Series C Preferred Stock		1,361,809		1,105,907
Conversion of Series D Preferred Stock		3,327,894		-
Stock-based compensation awards		1,135,415		623,111
Warrants to purchase Common Stock		659,806		659,806
Total		10,634,030		5,810,472

Note 8 - Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013

Research and development	$	47	$	14	$	68	$	98
General and administrative		138		7		166		28
Total	$	185	$	21	$	234	$	126

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2013		607,017		$	2.22		5.2	$	1,627
Granted		527,718		$	4.92
Exercised		(709	)	$	1.27
Cancelled or forfeited		-		$	-
Outstanding at September 30, 2014		1,134,026		$	3.49		6.9	$	8,716
Exercisable at September 30, 2014		581,438		$	2.38		4.5	$	5,123
Vested or expected to vest at September 30, 2014		1,067,423		$	3.33		6.8	$	8,264

Note 10 - Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Convertible Preferred stock		7,581		4,254		7,581		4,254
Common stock warrants		660		660		660		660
Outstanding stock options		1,134		607		1,134		607
Convertible notes		-		239		-		239
		9,375		5,760		9,375		5,760

Note 1 - Organization and Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Disclosure Text Block [Abstract]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.001	$ 0.001
Retained Earnings (Accumulated Deficit)	$ (116,540)	$ (100,514)
Cash, Cash Equivalents, and Short-term Investments	$ 21,700

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

Note 3 - Financial Instruments (Details) - Summary of Assets and Liabilities Measured at Fair Value - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Derivative Financial Instruments, Liabilities [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities
Liabilities	$ 11,903	$ 1,443
Derivative Financial Instruments, Liabilities [Member]
Financial liabilities
Liabilities	11,903	1,443
Fair Value, Inputs, Level 1 [Member] \| Cash Equivalents [Member]
Financial assets
Assets	3,233	2,781
Fair Value, Inputs, Level 1 [Member] \| US Government Agencies Debt Securities [Member]
Financial assets
Assets	18,447	2,359
Fair Value, Inputs, Level 1 [Member]
Financial assets
Assets	21,680	5,140
Fair Value, Inputs, Level 3 [Member]
Financial liabilities
Liabilities	11,903	1,443
Cash Equivalents [Member]
Financial assets
Assets	3,233	2,781
US Government Agencies Debt Securities [Member]
Financial assets
Assets	18,447	2,359
Assets	21,680	5,140
Financial liabilities
Liabilities	$ 11,903	$ 1,443

Note 4 - Convertible Notes (Details) - USD ($)				9 Months Ended
Note 4 - Convertible Notes (Details) - USD ($)	May 13, 2014	Sep. 04, 2013	Sep. 04, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Series D Preferred Stock [Member]
Note 4 - Convertible Notes (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 1.5
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	10,344,201
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.4414
Convertible Debt [Member]
Note 4 - Convertible Notes (Details) [Line Items]
Debt Instrument, Term				7 months
Other Assets [Member]
Note 4 - Convertible Notes (Details) [Line Items]
Deferred Finance Costs, Gross		$ 36,000	$ 36,000
Convertible Debt		$ 4.3	4.3
Proceeds from Convertible Debt			$ 4.3		$ 4,339,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
Discount on Convertible Debt		$ 10,000
Embedded Derivative, Fair Value of Embedded Derivative Liability		$ 1.4	$ 1.4			$ 1.4
Convertible Debt, Gain (Loss) Recognized	$ 0

Note 5 - Option to Acquire the Company (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2009	Mar. 31, 2009	Dec. 31, 2013
Business Combinations [Abstract]
Business Combination, Proceeds Received for Non Refundable Consideration, Option Agreement	$ 10,000
Business Combination, Fair Value of Option		$ 7,100
Deferred Revenue, Current	$ 2,900	$ 2,900	$ 2,948

Note 6 - Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands			2 Months Ended	3 Months Ended	9 Months Ended
	Oct. 21, 2014	May 13, 2014	Nov. 21, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Other Expense [Member] \| Series D Preferred Stock [Member] \| Rights [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Fair Value, Option, Changes in Fair Value, Gain (Loss) (in Dollars)				$ 5,300	$ 5,300
Redeemable Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				364,568,592	364,568,592
Series A Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				22,638,465	22,638,465	22,638,465
Temporary Equity, Par or Stated Value Per Share (in Dollars per share)				$ 0.001	$ 0.001	$ 0.001
Temporary Equity, Shares Issued				22,638,465	22,638,465	22,638,465
Series A-1 Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				10,909,091	10,909,091	10,909,091
Temporary Equity, Par or Stated Value Per Share (in Dollars per share)				$ 0.001	$ 0.001	$ 0.001
Temporary Equity, Shares Issued				10,909,091	10,909,091	10,909,091
Series B Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				20,754,461	20,754,461	20,754,461
Temporary Equity, Par or Stated Value Per Share (in Dollars per share)				$ 0.001	$ 0.001	$ 0.001
Temporary Equity, Shares Issued				20,754,461	20,754,461	20,754,461
Series C Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				17,550,758	17,550,758	17,550,758
Temporary Equity, Par or Stated Value Per Share (in Dollars per share)				$ 0.001	$ 0.001	$ 0.001
Temporary Equity, Shares Issued				13,202,932	13,202,932	13,202,932
Series D Preferred Stock [Member] \| Second and Third Tranches [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Proceeds from Issuance or Sale of Equity (in Dollars)		$ 20,000
Temporary Equity, Additional Shares Issuable		33,975,700
Series D Preferred Stock [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Temporary Equity, Shares Authorized				86,789,527	86,789,527	0
Temporary Equity, Par or Stated Value Per Share (in Dollars per share)				$ 0.001	$ 0.001	$ 0.001
Temporary Equity, Shares Issued		42,469,626		52,813,827	52,813,827	0
Share Price (in Dollars per share)		$ 0.588656
Proceeds from Issuance or Sale of Equity (in Dollars)		$ 25,000
Convertible Notes Payable, Noncurrent (in Dollars)		4,600
Interest on Convertible Debt, Net of Tax (in Dollars)		$ 200
Debt Conversion, Converted Instrument, Shares Issued		10,344,201
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 0.4414
(in Dollars)		$ 6,600
Payments of Stock Issuance Costs (in Dollars)		500
Amortization of Financing Costs and Discounts (in Dollars)		400
Allocated To Trance Right Liability (in Dollars)		$ 100
IPO [Member] \| Subsequent Event [Member]
Note 6 - Redeemable Convertible Preferred Stock (Details) [Line Items]
Share Price (in Dollars per share)	$ 10
Payments of Stock Issuance Costs (in Dollars)			$ 7,700
Conversion of Stock, Shares Issued	8,651,805
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		0.588656
(in Dollars)				$ 11,903	$ 11,903
Payments of Stock Issuance Costs (in Dollars)					$ 452

Note 6 - Redeemable Convertible Preferred Stock (Details) - Assumptions Used to Estimate Fair Value of Tranche Rights		9 Months Ended
	May 13, 2014	Sep. 30, 2014
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected term (in years)	1 year 306 days	1 year 124 days
Expected volatility	63.00%	63.00%
Risk-free interest rate	0.44%	0.34%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected term (in years)	3 years 6 months	3 years
Expected volatility	86.00%	71.00%
Risk-free interest rate	1.12%	1.05%
Expected dividend yield	0.00%	0.00%

Note 7 - Common Stock (Details) - $ / shares	Oct. 27, 2014	Sep. 30, 2014	Dec. 31, 2013
IPO [Member] \| Subsequent Event [Member]
Note 7 - Common Stock (Details) [Line Items]
Stock Issued During Period Shares Warrants Exercised	498,889
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 4.60
Common Stock, Shares, Outstanding		240,614	239,905
Common Stock, Shares Authorized		205,926,290	100,370,203
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001	$ 0.001
Common Stock, Shares, Issued		240,614	239,905

Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock - shares shares in Thousands	Sep. 30, 2014	Dec. 31, 2013
Series A Preferred Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	1,700,622	1,426,482
Series A-1 Preferred Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	838,101	687,395
Series B Preferred Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	1,610,383	1,307,771
Series C Preferred Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	1,361,809	1,105,907
Series D Preferred Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	3,327,894
Performance Shares [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	1,135,415	623,111
Warrants To Purchase Common Stock [Member]
Note 7 - Common Stock (Details) - Reserved for Future Issuances Shares of Common Stock [Line Items]
Shares reserved for future issuance	659,806	659,806
Shares reserved for future issuance	10,634,030	5,810,472

Note 8 - Stock-Based Compensation (Details) - Stock-Based Compensation Expense is Recognized for Stock Options Granted - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share based compensation	$ 47	$ 14	$ 68	$ 98
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share based compensation	138	7	166	28
Allocated share based compensation	$ 185	$ 21	$ 234	$ 126

Note 8 - Stock-Based Compensation (Details) - Stock Option Activity - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock Option Activity [Abstract]
Shares	1,134,026	607,017
Weighted-Average Exercise Price	$ 3.49	$ 2.22
Weighted- Average Remaining Contractual Term (years)	6 years 328 days	5 years 73 days
Aggregate Intrinsic Value	$ 8,716	$ 1,627
Granted	527,718
Granted	$ 4.92
Exercised	(709)
Exercised	$ 1.27
Exercisable at September 30, 2014	581,438
Exercisable at September 30, 2014	$ 2.38
Exercisable at September 30, 2014	4 years 6 months
Exercisable at September 30, 2014	$ 5,123
Vested or expected to vest at September 30, 2014	1,067,423
Vested or expected to vest at September 30, 2014	$ 3.33
Vested or expected to vest at September 30, 2014	6 years 292 days
Vested or expected to vest at September 30, 2014	$ 8,264

Note 9 - Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Note 9 - Income Taxes (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0	$ 0

Note 10 - Net Loss Per Share Attributable to Common Stockholders (Details) - Calculated of Net Loss Per Share - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,581	4,254	7,581	4,254
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	660	660	660	660
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,134	607	1,134	607
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities		239		239
Antidilutive Securities	9,375	5,760	9,375	5,760

Note 11 - Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended	9 Months Ended
	Oct. 27, 2014	Oct. 21, 2014	Oct. 03, 2014	Nov. 21, 2014	Sep. 30, 2014	Dec. 31, 2013
IPO [Member] \| Subsequent Event [Member]
Note 11 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	6,110,000	7,026,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		916,500
Share Price (in Dollars per share)		$ 10
Stock Issued During Period, Value, New Issues (in Dollars)		$ 70,300
Proceeds from Issuance of Common Stock (in Dollars)				$ 62,500
Payments of Stock Issuance Costs (in Dollars)				$ 7,700
Stock Issued During Period Shares Warrants Exercised	498,889
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 4.60
Conversion of Stock, Shares Issued		8,651,805
Subsequent Event [Member] \| Maximum [Member] \| The 2014 Employee Stock Purchase Plan [Member]
Note 11 - Subsequent Events (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			281,000
Subsequent Event [Member] \| The 2014 Employee Stock Purchase Plan [Member]
Note 11 - Subsequent Events (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			704,000
Common Stock, Capital Shares Reserved for Future Issuance, Outstanding Common Stock, Percentage			4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			140,500
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Common Stock Outstanding, Percentage			1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					709
Payments of Stock Issuance Costs (in Dollars)					$ 452
Common Stock, Capital Shares Reserved for Future Issuance					10,634,030,000	5,810,472,000